Active Not Recruiting
PHASE2
INTERVENTIONAL
NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Interventions
Name:
CagriSema (Cagrilintide B and Semaglutide I)
Type:
DRUG
Description:
Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Name:
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Type:
DRUG
Description:
Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Primary Outcomes
Measure:
Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)
TimeFrame:
From baseline (week 0) to end of treatment (week 32)
Description:
Measured as score on a scale.
Trial Information
NCT ID
NCT06797869
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025